Apotex Ruxolitinib Resubmission Status
Apotex resubmitted its abbreviated new drug application (ANDA) for a generic version of Incyte/BMS's Jakafi (ruxolitinib) tablets in Class 2 response to FDA's complete response letter. The FDA set a target action date of March 29, 2025, under the 6-month review timeline for resubmissions.[1][2]
Why the March 2025 Target?
The resubmission occurred on September 27, 2024, triggering the FDA's standard 6-month review for Class 2 ANDAs, which involve manufacturing or labeling issues. This date aligns with prior FDA filings and avoids patent cliffs tied to Jakafi's main patents expiring in 2027–2028.[1][3]
Patent Challenges Ahead
Even if approved, Apotex faces Hatch-Waxman litigation from Incyte and Novartis. Key U.S. patents on ruxolitinib (e.g., 8,158,616 for the phosphate salt form) extend to 2027, with pediatric exclusivity pushing to January 2028. Apotex is the first generic filer with 180-day exclusivity potential if it prevails.[4][5]
How Does Apotex's Filing Compare to Other Generics?
Apotex leads among challengers, ahead of Sandoz (rejected in 2023) and others like MSN and Lupin. No generics are approved yet; earliest market entry hinges on court wins post-FDA nod.[2][6]
What Happens if FDA Delays or Rejects?
FDA decisions can slip due to inspections or data requests—seen in 40% of recent ANDA resubmissions. Rejection would reset the clock; approval launches Paragraph IV battle, delaying launch 30+ months on average.[3][7]
Sources
[1]: FDA Purple Book and ANDA Tracker
[2]: DrugPatentWatch.com - Ruxolitinib ANDA Status
[3]: FDA ANDA Review Timelines
[4]: DrugPatentWatch.com - Jakafi Patents
[5]: USPTO Patent Database
[6]: Par Pharmaceutical Litigation Updates
[7]: GAO Report on ANDA Delays